Abzena PLC (LSE:ABZA) - Share price - Overview

Stock Report

Abzena PLC ABZA

Last Price
GBX39.50

Day Change
0.00|0.00%

As of 17/02/2017
13:29:26 GMT | GBX
Minimum 15 Minutes Delay.

Last Close39.50p
Day Range39.11 - 39.48
Mkt Cap54.45Mil
52-Wk Range31.00 - 66.00
Yield %0.00
ISINGB00BN65QN46
Volume10,679
P/E-5.92
P/S4.38
P/CF-4.13

Share Price

Total Returns 17/02/2017

 Chg (%)  
More ...
Abzena PLC9.72 
FTSE 100 TR GBP1.55
 
Financials
201420152016
More ...
Income Statement
Turnover4.225.679.85
Operating Profit-3.31-5.30-10.90
Net Profit-2.85-4.72-9.70
Reported EPS-2.92-7.00-9.00
Balance Sheet
Current Assets5.8620.9222.11
Non Current Assets10.1410.4327.35
Total Assets16.0031.3649.46
Current Liabilities1.282.355.85
Total Liabilities2.463.518.40
Total Equity13.5327.8541.06
Cash Flow
Operating Cash Flow-3.47-4.86-10.87
Net Change in Cash0.1813.04-2.08
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-8.50-5.44--7.27---
2018-6.10-3.83--10.31---

Regulatory News

DateSourceHeadline
More ...
06/02/2017|10:55RNSAbzena PLC - Total Voting Rights
24/01/2017|07:00RNSAbzena PLC - Issue of Equity
20/01/2017|07:00RNSAbzena PLC - ThioBridge license agreement
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
01/04/2016Exercise of OptionMr. Julian Smith0.00233,0320.00
01/04/2016Exercise of OptionDr. William Burt0.00424,5370.00

Company Profile

Abzena PLC is a life sciences company. The Company through its subsidiaries provides immunogenicity assessment, protein engineering and cell line development, and a suite of bioconjugation technologies.

Sector

Biotechnology

Market Position

1074 of 1851 Companies

Index

Outlook

(30/11/2016) "...the board is confident that there is substantial further growth potential for the business"

Next Event 31/03/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-9.8414.3016.11
Div Yld (E)0.003.764.04
PEG (E)0.00-0.601.59
ROCE-40.67202.24107.14
Op Mrgn-82.69-12.26-17.07
EPS Grwth0.0040.8828.56
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Ken Cunningham
Chief Executive OfficerDr. William Burt
Chief Financial Officer & Company SecretMr. Julian Smith
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.